Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Mar 25, 2025; 14(1): 101515
Published online Mar 25, 2025. doi: 10.5527/wjn.v14.i1.101515
Optimizing chronic kidney disease management: The potential of a multi-strain probiotic formulation
Deodatta Chafekar
Deodatta Chafekar, Dr V N Pawar Medical College, Director Supreme Kidney Care, Nashik 422005, Mahārāshtra, India
Author contributions: Chafekar D made substantial contributions to the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revisions related to important intellectual content; and the author provided final approval for the version to be published.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deodatta Chafekar, MD, Professor, Dr V N Pawar Medical College, Director Supreme Kidney Care, OM Chambers, Opp. Holaram Colony, Sharanpur, Nashik 422005, Mahārāshtra, India. nchafy@hotmail.com
Received: September 17, 2024
Revised: October 21, 2024
Accepted: December 3, 2024
Published online: March 25, 2025
Processing time: 124 Days and 20.7 Hours
Core Tip

Core Tip: Chronic kidney disease (CKD) is a major global health challenge marked by a gradual decline in kidney function and associated complications. Recent studies have suggested that dysbiosis of the gut microbiota plays a significant role in CKD progression to end-stage renal disease. Probiotics and prebiotics, particularly strains such as Lactobacillus and Bifidobacterium and combinations including Streptococcus thermophilus and Bacillus coagulans, show promise in managing CKD by restoring the gut microbiota balance. Although these findings are promising, further research is essential to comprehensively understand the impact of specific probiotic formulations on CKD outcomes and their potential as therapeutic interventions.